We have recently reported that tumor-associated lymphocytes obtained from ascitic fluids of women with ovarian carcinoma (OvCA) demonstrate a marked decrease in expression of cytoplasmic CD3-zeta and surface CD3-epsilon chains, which is associated with altered function of T cell receptor (TcR). We now demonstrate that OvCAs in situ and in culture express functional Fas ligand (FasL), capable of triggering an intrinsic cell death program in Fas-expressing T cells. The possibility of a relationship between cell death and altered expression of TcR was examined. The data indicate that alterations in expression of CD3-zeta and CD3-epsilon chains in T cells coincubated with OvCA are related to tumor-induced apoptosis, as the addition of pan-caspase inhibitors, DEVD-cho or YVAD-cho, prevents both the in vitro induction of T cell death by OvCA cells and the changes in the level of expression of CD3-zeta and CD3-epsilon chains. In the presence of Fas-Fc fusion protein, but not Fc-control protein, the loss in expression of CD3-zeta and CD3-epsilon chains induced in T cells by FasL+ OvCA cells was prevented. These results suggest that the loss in expression of CD3-zeta and CD3-epsilon chains in T lymphocytes interacting with OvCA cells is associated with apoptosis mediated by FasL-expressing tumor cells.
H Rabinowich, T E Reichert, Y Kashii, B R Gastman, M C Bell, T L Whiteside
Title and authors | Publication | Year |
---|---|---|
Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function
Degirmencay A, Thomas S, Holler A, Burgess S, Morris EC, Stauss HJ |
Frontiers in immunology | 2024 |
FASLG as a Key Member of Necroptosis Participats in Acute Myocardial Infarction by Regulating Immune Infiltration
Jia HM, An FX, Zhang Y, Yan MZ, Zhou Y, Bian HJ |
Cardiology Research | 2024 |
Genetic Polymorphism and cancer susceptibility
AS Sameer, MZ Banday, S Nissar |
2021 | |
The Proposition of the Pulmonary Route as an Attractive Drug Delivery Approach of Nano-Based Immune Therapies and Cancer Vaccines to Treat Lung Tumors
M Donkor, HP Jones |
2021 | |
Immunotyping in tubo‐ovarian high‐grade serous carcinoma by PD‐L1 and CD8+ T‐lymphocytes predicts disease‐free survival
A Bansal, R Srinivasan, M Rohilla, B Rai, A Rajwanshi, V Suri, SC Saha |
APMIS | 2021 |
Myeloid Cell-Derived Arginase in Cancer Immune Response
TM Grzywa, A Sosnowska, P Matryba, Z Rydzynska, M Jasinski, D Nowis, J Golab |
Frontiers in immunology | 2020 |
Antitumour dendritic cell vaccination in a priming and boosting approach
A Harari, M Graciotti, M Bassani-Sternberg, LE Kandalaft |
Nature Reviews Drug Discovery | 2020 |
Defects at the Posttranscriptional Level Account for the Low TCRζ Chain Expression Detected in Gastric Cancer Independently of Caspase-3 Activity
A Aguinaga-Barrilero, P Castro-Sánchez, I Juárez, A Gutiérrez-Calvo, N Rodríguez-Pérez, A Lopez, R Gómez, JM Martin-Villa, P Wlasiuk |
Journal of Immunology Research | 2020 |
CD247 expression is associated with differentiation and classification in ovarian cancer:
W Ye, Y Zhou, B Xu, D Zhu, X Rui, M Xu, L Shi, D Zhang, J Jiang |
Medicine | 2019 |
The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia
FR Villagomez, O Medina-Contreras, JF Cerna-Cortes, G Patino-Lopez |
Small GTPases | 2018 |
Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma
C Cai, J Zhang, M Li, ZJ Wu, KH Song, TW Zhan, LH Wang, YH Sun |
Tumor Biology | 2015 |
Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer
Guang-Zhou Wu, Chun-Xia Pan, Dong Jiang, Qiang Zhang, Yin Li, Shi-Ying Zheng |
American journal of cancer research | 2015 |
Association of the Polymorphisms in the Fas/FasL Promoter Regions with Cancer Susceptibility: A Systematic Review and Meta-Analysis of 52 Studies
Y Xu, B He, R Li, Y Pan, T Gao, Q Deng, H Sun, G Song, S Wang, QY Wei |
PloS one | 2014 |
Fas −670A/G (rs1800682) Polymorphism and Digestive Cancer Risk in Asians: A Meta-Analysis
HP Yuan, QD Liu, GQ Li, YQ Cong |
Genetic Testing and Molecular Biomarkers | 2014 |
Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population
J Wang, J Gao, Y Li, X Zhao, W Gao, L Peng, D Yan, L Liu, D Li, L Wei, J Qi, C Zhou |
Gene | 2013 |
Fas ligand+ fallopian tube epithelium induces apoptosis in both Fas receptor+ T lymphocytes and endometrial cells
SE Illanes, K Maisey, M Sandoval, FE Reyes, C Figueroa-Gaete, A Pérez-Sepúlveda, M Busquets, P González, M Imarai |
Fertility and Sterility | 2013 |
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
LE Kandalaft, CL Chiang, J Tanyi, G Motz, K Balint, R Mick, G Coukos |
Journal of Translational Medicine | 2013 |
Expression of co-stimulators CD28/B7-1 in peripheral blood of patients with breast cancer
J Gong, W Pan, C Yang, F Guo, Y Sun |
Breast Cancer Research and Treatment | 2012 |
Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes
Y Li, Y Hao, S Kang, R Zhou, N Wang, B Qi |
Gynecologic Oncology | 2012 |
Human FasL Gene Is a Target of β-Catenin/T-Cell Factor Pathway and Complex FasL Haplotypes Alter Promoter Functions
J Wu, MH Richards, J Huang, L Al-Harthi, X Xu, R Lin, F Xie, AW Gibson, JC Edberg, RP Kimberly, C Gottardi |
PloS one | 2011 |
Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy
VT Cheriyan, C Thomas, P Balaram |
Journal of Cancer Research and Clinical Oncology | 2011 |
Attack the Tumor Counterattack-C-Flip Expression in Jurkat-T-Cells Protects Against Apoptosis Induced by Coculture with SW620 Colorectal Adenocarcinoma Cells
AE Steiert, D Sendler, WF Burke, CY Choi, K Reimers, PM Vogt |
Journal of Surgical Research | 2011 |
Interleukin-13 Induces T Helper Type 2 Immune Responses in OVA-Immunized BALB/c Mice Bearing a T Cell Lymphoma : IL-13 Induces Th2 Type Immune Responses
P Deepak, A Acharya |
Scandinavian Journal of Immunology | 2011 |
Cancer of the Skin
B Berman, M Viera, S Amini, W Valins |
Cancer of the Skin | 2011 |
Cell Signaling & Molecular Targets in Cancer
M Chatterjee, K Kashfi |
2011 | |
Whole tumor antigen vaccines
CL Chiang, F Benencia, G Coukos |
Seminars in Immunology | 2010 |
CD95 promotes tumour growth
L Chen, SM Park, AV Tumanov, A Hau, K Sawada, C Feig, JR Turner, YX Fu, IL Romero, E Lengyel, ME Peter |
Nature | 2010 |
The role of immunity in elderly cancer
L Malaguarnera, E Cristaldi, M Malaguarnera |
Critical Reviews in Oncology/Hematology | 2010 |
Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma
J Zhu, C Qin, M Wang, F Yan, X Ju, X Meng, Q Ding, P Li, J Yang, Q Cao, Z Zhang, C Yin |
Molecular Carcinogenesis | 2010 |
Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma
RM Zhou, N Wang, ZF Chen, YN Duan, DL Sun, Y Li |
Journal of Gastroenterology and Hepatology | 2010 |
Tumor-Shed PGE2 Impairs IL2Rγc-Signaling to Inhibit CD4+ T Cell Survival: Regulation by Theaflavins
S Chattopadhyay, S Bhattacharyya, B Saha, J Chakraborty, S Mohanty, DM Hossain, S Banerjee, K Das, G Sa, T Das, JA Bauer |
PloS one | 2009 |
Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients
WK Yip, MA Abdullah, SM Yusoff, HF Seow |
Clinical & Experimental Immunology | 2009 |
Tricks tumors use to escape from immune control
TL Whiteside |
Oral Oncology | 2009 |
T Cell Density and Location Can Influence the Prognosis of Ovarian Cancer
A Al-Attar, M Shehata, L Durrant, P Moseley, S Deen, S Chan |
Pathology & Oncology Research | 2009 |
Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer
AE Albers, C Schaefer, C Visus, W Gooding, AB DeLeo, TL Whiteside |
Head & Neck | 2009 |
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
PC Rodríguez, AC Ochoa |
Immunological Reviews | 2008 |
Cancer Immunology
OJ Finn |
New England Journal of Medicine | 2008 |
The impact of T-cell immunity on ovarian cancer outcomes
BH Nelson |
Immunological Reviews | 2008 |
Modulation of cell growth and apoptosis response in human prostate cancer cells supplemented with tocotrienols
K Nesaretnam, TH Koon, KR Selvaduray, RS Bruno, E Ho |
European Journal of Lipid Science and Technology | 2008 |
Innate and Adaptive Immunity in the Tumor Microenvironment
E Yefenof |
2008 | |
Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways
T Das, G Sa, E Paszkiewicz-Kozik, C Hilston, L Molto, P Rayman, D Kudo, K Biswas, RM Bukowski, JH Finke, CS Tannenbaum |
Journal of immunology (Baltimore, Md. : 1950) | 2008 |
The Role of Death Receptor Ligands in Shaping Tumor Microenvironment
TL Whiteside |
Immunological Investigations | 2007 |
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
V Minas, A Rolaki, SN Kalantaridou, J Sidiropoulos, S Mitrou, G Petsas, U Jeschke, EA Paraskevaidis, G Fountzilas, GP Chrousos, N Pavlidis, A Makrigiannakis |
British Journal of Cancer | 2007 |
Cancer Immunotherapy
S Mandruzzato, S Mocellin, V Bronte |
Cancer Immunotherapy | 2007 |
Curcumin Prevents Tumor-induced T Cell Apoptosis through Stat-5a-mediated Bcl-2 Induction
S Bhattacharyya, D Mandal, B Saha, GS Sen, T Das, G Sa |
The Journal of biological chemistry | 2007 |
General Principles of Tumor Immunotherapy
HL Kaufman, JD Wolchok |
2007 | |
Phosphatidylinositol 3-Kinase/Akt Activation by Integrin-Tumor Matrix Interaction Suppresses Fas-Mediated Apoptosis in T Cells
CC Su, YP Lin, YJ Cheng, JY Huang, WJ Chuang, YS Shan, BC Yang |
Journal of immunology (Baltimore, Md. : 1950) | 2007 |
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
MG Hanson, V Özenci, MC Carlsten, BL Glimelius, JE Frödin, G Masucci, KJ Malmberg, RV Kiessling |
Cancer Immunology, Immunotherapy | 2006 |
The cancer stem cell: evidence for its origin as an injured autoreactive T cell
P Grandics |
Molecular Cancer | 2006 |
The tumour microenvironment and implications for cancer immunotherapy
CA Petrulio, S Kim-Schulze, HL Kaufman |
Expert Opinion on Biological Therapy | 2006 |
Tumor immune escape mechanisms: impact of the neuroendocrine system
K Lang, F Entschladen, C Weidt, KS Zaenker |
Cancer Immunology, Immunotherapy | 2006 |
HSP-10 in ovarian cancer: Expression and suppression of T-cell signaling
S Akyol, C Gercel-Taylor, LC Reynolds, DD Taylor |
Gynecologic Oncology | 2006 |
Tumor Infiltrating Lymphocytes in Uveal Melanoma: A Link with Clinical Behavior?
S Staibano, M Mascolo, F Tranfa, G Salvatore, C Mignogna, P Bufo, L Nugnes, G Bonavolontà, GD Rosa |
International journal of immunopathology and pharmacology | 2006 |
Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling
DD Taylor, S Akyol, C Gercel-Taylor |
Journal of immunology (Baltimore, Md. : 1950) | 2006 |
Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects
DD Taylor, C Gerçel-Taylor |
British Journal of Cancer | 2005 |
Current concepts of tumor-infiltrating lymphocytes in human malignancies
SH Chiou, BC Sheu, WC Chang, SC Huang, H Hong-Nerng |
Journal of Reproductive Immunology | 2005 |
Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer
K Sonoda, S Miyamoto, T Hirakawa, H Yagi, F Yotsumoto, M Nakashima, T Watanabe, H Nakano |
Gynecologic Oncology | 2005 |
FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer
T Sun, Y Zhou, H Li, X Han, Y Shi, L Wang, X Miao, W Tan, D Zhao, X Zhang, Y Guo, D Lin |
Journal of Experimental Medicine | 2005 |
Tumor Immunology and Cancer Vaccines
SN Khleif |
2005 | |
Apoptosis of Lymphocytes in Peripheral Blood of Patients with Melanoma
F Tas, D Duranyildiz, A Argon, H Oguz, H Camlica, V Yasasever, E Topuz |
Medical Oncology | 2005 |
Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells
JR Conejo-Garcia, F Benencia, MC Courreges, PA Gimotty, E Khang, RJ Buckanovich, KA Frauwirth, L Zhang, D Katsaros, CB Thompson, B Levine, G Coukos |
Cancer research | 2004 |
CD95L mediates tumor counterattackin vitro but induces neutrophil-independent tumor rejectionin vivo
FH Igney, CK Behrens, PH Krammer |
International Journal of Cancer | 2004 |
Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma
AC Satchell, RS Barnetson, GM Halliday |
British Journal of Dermatology | 2004 |
Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
AD Santin, S Bellone, M Palmieri, B Bossini, S Cane', E Bignotti, JJ Roman, MJ Cannon, S Pecorelli |
International Journal of Gynecological Cancer | 2004 |
Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients
A Maki, M Matsuda, M Asakawa, H Kono, H Fujii, Y Matsumoto |
Journal of Gastroenterology and Hepatology | 2004 |
Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer
H Sugai, K Kono, A Takahashi, F Ichihara, H Kawaida, H Fujii, Y Matsumoto |
Journal of Surgical Research | 2004 |
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes
Y Meng, L Graves, TV Do, J So, DA Fishman |
Gynecologic Oncology | 2004 |
Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions
JJ Sikora, GT Dworacki, MT Kaczmarek, RE Jenek, JO Żeromski |
Cancer Detection and Prevention | 2004 |
Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients
DD Taylor, RP Edwards, CR Case, Ç Gerçel-Taylor |
Gynecologic Oncology | 2004 |
The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack
MJ Martı́nez-Lorenzo, A Anel, MA Alava, A Piñeiro, J Naval, P Lasierra, L Larrad |
Experimental Cell Research | 2004 |
Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes
A Riccobon, R Gunelli, R Ridolfi, FD Paola, E Flamini, M Fiori, C Saltutti, M Petrini, L Fiammenghi, M Stefanelli, AM Granato, DE Cuzzocrea, D Amadori |
Cancer Investigation | 2004 |
Cancer Immunotherapy at the Crossroads
JH Finke, RM Bukowski |
2004 | |
Characterization of Defective CD4 − CD8 − T Cells in Murine Tumors Generated Independent of Antigen Specificity
RM Prins, F Incardona, R Lau, P Lee, S Claus, W Zhang, KL Black, CJ Wheeler |
Journal of immunology (Baltimore, Md. : 1950) | 2004 |
Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer?
Whiteside TL |
Cancer Immunology, Immunotherapy | 2004 |
Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape?
Malmberg KJ |
Cancer Immunology, Immunotherapy | 2004 |
The Fas/Fas Ligand System and Cancer: Immune Privilege and Apoptosis
VM Abrahams, M Kamsteeg, G Mor |
Molecular Biotechnology | 2003 |
Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck
I Kuss, AD Donnenberg, W Gooding, TL Whiteside |
British Journal of Cancer | 2003 |
Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
FD Paola, R Ridolfi, A Riccobon, E Flamini, F Barzanti, AM Granato, GL Mordenti, L Medri, P Vitali, D Amadori |
British Journal of Cancer | 2003 |
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
L Zhang, JR Conejo-Garcia, D Katsaros, PA Gimotty, M Massobrio, G Regnani, A Makrigiannakis, H Gray, K Schlienger, MN Liebman, SC Rubin, G Coukos |
New England Journal of Medicine | 2003 |
Human Urinary Bladder Transitional Cell Carcinomas Acquire the Functional Fas Ligand during Tumor Progression
D Chopin, R Barei-Moniri, P Maillé, MA Frère-Belda, B Muscatelli-Groux, N Merendino, L Lecerf, A Stoppacciaro, F Velotti |
The American Journal of Pathology | 2003 |
Cancer Chemotherapy and Biological Response Modifiers Annual
MS Turner, JR McKolanis, RK Ramanathan, DC Whitcomb, OJ Finn |
Cancer Chemotherapy and Biological Response Modifiers Annual Volume 21 | 2003 |
Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium
JS Yu, PK Lee, M Ehtesham, K Samoto, KL Black, CJ Wheeler |
Journal of Neuro-Oncology | 2003 |
Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer:
KM Sheehan, DG O'Donovan, G Fitzmaurice, A O'Grady, DP O'Donoghue, K Sheahan, MF Byrne, RM Conroy, EW Kay, FE Murray |
European Journal of Gastroenterology & Hepatology | 2003 |
Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment
L Pignataro, E Arisi, G Sambataro, MM Corsi |
Journal of Surgical Oncology | 2003 |
Covalent linking of proteins and cytokines to suture: Enhancing the immune response of head and neck cancer patients
TY Shibuya, S Kim, K Nguyen, P Parikh, A Wadhwa, C Brockardt, J Do |
The Laryngoscope | 2003 |
Expression of Fas and FasL in human serous ovarian epithelial tumors
C Haaften-Day, P Russell, S Davies, NJ King, MH Tattersall |
Human Pathology | 2003 |
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia
GF Torelli, R Paolini, C Tatarelli, A Soriani, A Vitale, A Guarini, A Santoni, R Foa |
British Journal of Haematology | 2003 |
Immunologic principles and immunotherapeutic approaches in ovarian cancer
Keith L Knutson, Tyler J Curiel, Lupe Salazar, Mary L Disis |
Hematology/Oncology Clinics of North America | 2003 |
Regulation of FasL/Fas in Human Trophoblasts: Possible Implications for Chorioamnionitis1
DR Balkundi, JA Ziegler, JF Watchko, C Craven, M Trucco |
Biology of reproduction | 2003 |
Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
FD Paola, R Ridolfi, A Riccobon, E Flamini, F Barzanti, AM Granato, GL Mordenti, L Medri, P Vitali, D Amadori |
British Journal of Cancer | 2003 |
Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck
I Kuss, AD Donnenberg, W Gooding, TL Whiteside |
British Journal of Cancer | 2003 |
Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer
A Takahashi, K Kono, F Ichihara, H Sugai, H Amemiya, H Iizuka, H Fujii, Y Matsumoto |
International Journal of Cancer | 2003 |
Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium.
Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ |
Journal of Neuro-Oncology | 2003 |
Tumour escape: antitumour effectors too much of a good thing?
Pawelec G |
Cancer Immunology, Immunotherapy | 2003 |
Rapid turnover of the CD8+CD28- T-cell subset of effector cells in the circulation of patients with head and neck cancer
Tsukishiro T, Donnenberg AD, Whiteside TL |
Cancer Immunology, Immunotherapy | 2003 |
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
KJ Malmberg, V Levitsky, H Norell, CT de Matos, M Carlsten, K Schedvins, H Rabbani, A Moretta, K Söderström, J Levitskaya, R Kiessling |
Journal of Clinical Investigation | 2002 |
Fas receptor-mediated apoptosis: a clinical application?
T Timmer, EG de Vries, S Jong |
The Journal of Pathology | 2002 |
Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer
N Meidenbauer, W Gooding, L Spitler, D Harris, TL Whiteside |
British Journal of Cancer | 2002 |
Modulation of T-cell CD3-zeta chain expression during normal pregnancy
DD Taylor, SA Sullivan, AC Eblen, C Gercel-Taylor |
Journal of Reproductive Immunology | 2002 |
Shed membrane fragment modulation of CD3-zeta during pregnancy: link with induction of apoptosis
C Gercel-Taylor, SM O'Connor, GK Lam, DD Taylor |
Journal of Reproductive Immunology | 2002 |
The biological role of the Fas/FasL system during tumor formation and progression
E Reichmann |
Seminars in Cancer Biology | 2002 |
Expression of Functional Fas Ligand in Choriocarcinoma
A Hammer, M Hartmann, P Sedlmayr, W Walcher, G Kohnen, G Dohr |
American Journal of Reproductive Immunology | 2002 |
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) expression
HR Salih, GC Starling, SF Brandl, R Pelka-Fleischer, T Haferlach, W Hiddemann, PA Kiener, V Nuessler |
British Journal of Haematology | 2002 |
Expression of the signal transduction molecule zeta in peripheral and tumour-associated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr virus status of the tumour cells
J Sjoberg, M Andersson, C Garcia, KA Palucka, M Bjorkholm, A Porwit-MacDonald, P Pisa |
British Journal of Haematology | 2002 |
Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy
TL Whiteside |
Vaccine | 2002 |
Expression of ζ in T Cells Prior to Interleukin-2 Therapy as a Predictor of Response and Survival in Patients with Ovarian Carcinoma
I Kuss, H Rabinowich, W Gooding, R Edwards, TL Whiteside |
Cancer Biotherapy & Radiopharmaceuticals | 2002 |
Tumor-induced death of immune cells: its mechanisms and consequences
TL Whiteside |
Seminars in Cancer Biology | 2002 |
CD3-?chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients
S Ishigami, S Natsugoe, K Tokuda, A Nakajo, H Higashi, H Iwashige, K Aridome, S Hokita, T Aikou |
Cancer | 2002 |
Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer
M Ehtesham, K Samoto, P Kabos, FL Acosta, MA Gutierrez, KL Black, JS Yu |
Cancer Gene Therapy | 2002 |
Cancer vaccines and immunotherapy
S Dermime, A Armstrong, RE Hawkins, PL Stern |
British Medical Bulletin | 2002 |
Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients
DD Taylor, DP Bender, GT C, J Stanson, TL Whiteside |
British Journal of Cancer | 2001 |
The role of Fas and FasL as mediators of anticancer chemotherapy
V Poulaki, CS Mitsiades, N Mitsiades |
Drug Resistance Updates | 2001 |
Apoptosis and its clinical impact
BR Gastman |
Head & Neck | 2001 |
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug
N Mitsiades, KC Anderson, V Poulaki, CS Mitsiades |
Expert Opinion on Investigational Drugs | 2001 |
Head and Neck Cancer
A Forastiere, W Koch, A Trotti, D Sidransky |
New England Journal of Medicine | 2001 |
Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression
MH Andersen, P Keikavoussi, EB Br�cker, B Schuler-Thurner, M Jonassen, I S�ndergaard, P Straten, JC Becker, E K�mpgen |
International Journal of Cancer | 2001 |
Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer
AD Santin, S Bellone, A Ravaggi, J Roman, CV Smith, S Pecorelli, MJ Cannon, GP Parham |
BJOG: An International Journal of Obstetrics and Gynaecology | 2001 |
Loss of T-cell receptor-CD3ζ and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma
DC Lockhart, AK Chan, S Mak, HG Joo, HA Daust, A Carritte, CC Douville, PS Goedegebuure, TJ Eberlein |
Surgery | 2001 |
Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer
AD Santin, S Bellone, A Ravaggi, J Roman, CV Smith, S Pecorelli, MJ Cannon, GP Parham |
British Journal of Obstetrics and Gynaecology | 2001 |
Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95-Sensitive Cells
HR Salih, GC Starling, M Knauff, MB Llewellyn, PM Davis, WJ Pitts, A Aruffo, PA Kiener |
Experimental Cell Research | 2001 |
CD8 + Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ
S Radoja, M Saio, AB Frey |
Journal of immunology (Baltimore, Md. : 1950) | 2001 |
Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis
X Chen, A Woiciechowsky, S Raffegerst, D Schendel, HJ Kolb, M Roskrow |
British Journal of Haematology | 2000 |
CD95 ligand expression as a mechanism of immune escape in breast cancer
M Müschen, C Moers, U Warskulat, J Even, D Niederacher, MW Beckmann |
Immunology | 2000 |
Nonlymphoid cultured cells possess a system controlling cellular compatibility
LP Sashchenko, EA Dukhanina, ES Ioudinkova, OV Iarovaia, TI Lukianova, OD Kabanova, NV Gnuchev, SV Razin |
Journal of Cellular Biochemistry | 2000 |
Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell Death
W Stohl, D Xu, GC Starling, P Casali, PA Kiener |
Cellular Immunology | 2000 |
Immunology and immunotherapy of human cancer: present concepts and clinical developments
AJ Bremers, G Parmiani |
Critical Reviews in Oncology/Hematology | 2000 |
Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
K Hellstrand, M Brune, C Dahlgren, M Hansson, S Hermodsson, P Lindnér, UH Mellqvist, P Naredi |
Medical Oncology | 2000 |
Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events
BR Gastman, DE Johnson, TL Whiteside, H Rabinowich |
Blood | 2000 |
Circulating soluble Fas ligand in patients with gastric carcinoma
S Tsutsumi, H Kuwano, T Shimura, N Morinaga, E Mochiki, T Asao |
Cancer | 2000 |
B7.1 on Human Carcinomas: Costimulation of T Cells and Enhanced Tumor-Induced T-Cell Death
S Lang, Y Atarashi, Y Nishioka, J Stanson, N Meidenbauer, TL Whiteside |
Cellular Immunology | 2000 |
Antigen-Specific Induction of Peripheral T Cell Tolerance in Vivo by Codelivery of DNA Vectors Encoding Antigen and Fas Ligand
RW Georgantas, KW Leong, JT August |
Human Gene Therapy | 2000 |
Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen
G Mor, F Kohen, J Garcia-Velasco, J Nilsen, W Brown, J Song, F Naftolin |
The Journal of Steroid Biochemistry and Molecular Biology | 2000 |
Specificity questions concerning the clone 33 anti-fas ligand antibody
JR Baker, JD Bretz |
Cell Death and Differentiation | 2000 |
Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing
S Radoja, AB Frey |
Molecular Medicine | 2000 |
Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway
N Favre-Felix, A Fromentin, A Hammann, E Solary, F Martin, B Bonnotte |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
Type 1 and Type 2 CD8 + Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor
MJ Dobrzanski, JB Reome, RW Dutton |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack
O'connell, Bennett, O'sullivan, Collins, Shanahan |
Diseases of the Esophagus | 1999 |
Fas-Mediated Induction of Hepatocyte Apoptosis in a Neuroblastoma and Hepatocyte Coculture Model
MK Chen, LF Strande, EA Beierle, MS Kain, BD Geldziler, EJ Doolin |
Journal of Surgical Research | 1999 |
Alterations in NF B Activation in T Lymphocytes of Patients With Renal Cell Carcinoma
RG Uzzo, PE Clark, P Rayman, T Bloom, L Rybicki, AC Novick, RM Bukowski, JH Finke |
JNCI Journal of the National Cancer Institute | 1999 |
Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors
N Mitsiades, V Poulaki, A Leone, M Tsokos |
JNCI Journal of the National Cancer Institute | 1999 |
The Fas counterattack: cancer as a site of immune privilege
J O’Connell, MW Bennett, GC O’Sullivan, JK Collins, F Shanahan |
Immunology Today | 1999 |
FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection
N Favre, B Bonnotte, N Droin, A Fromentin, E Solary, F Martin |
International Journal of Cancer | 1999 |
Tumor Necrosis Factor-α and Interferon-γ Induce Expression of Functional Fas Ligand on HT29 and MCF7 Adenocarcinoma Cells
C Naujokat, O Sezer, K Possinger |
Biochemical and Biophysical Research Communications | 1999 |
Predominant Expression of Fas (CD95) Ligand in Metastatic Melanoma Revealed by Longitudinal Analysis
P Terheyden, C Siedel, A Merkel, E Kampgen, EB Brocker, JC Becker |
Journal of Investigative Dermatology | 1999 |
Immunology for Surgeons
JE Castro |
1976 |